Advancing Novel NLRP3 Inflammasome Therapeutics

Halia has applied our extensive structure-based design experience to advance multiple drug candidates to clinical development. Halia’s exciting new therapies are designed to treat severe inflammatory diseases and cancers. Halia’s programs focus on clinically validated novel protein targets that drive the pathogenesis of multiple serious human diseases. Our lead clinical program targets the assembly of the NLRP3 inflammasome through a novel mechanism of NEK7 allosteric inhibition. By blocking the interaction of NEK7 and NLRP3, we prevent the formation of the inflammasome and the downstream signaling that drives immune-inflammatory diseases, hematologic malignancies, and even cancer development.


We have leveraged our core capabilities in targeting the underlying causes of inflammation and neurological diseases to build a discovery engine that has produced a pipeline of novel therapies we are advancing into the clinic.


We are growing to become a leader in targeting the NLRP3 inflammasome through a unique mechanism of action.


We use an innovative approach to drug discovery by translating advances in the understanding of the importance of inflammation in human pathologies such as cancer and neurodegenerative diseases.

Discovering New Meaningful Medicines

Halia Therapeutics is a clinical-stage biopharmaceutical company with a ground-breaking and transformative approach to targeting chronic inflammation. Our pipeline of products allows for treating chronic disease in new ways by turning off the inflammatory signaling at the source. Our team has developed a proprietary approach to inhibit inflammation, which has led to the design of potent and selective, small-molecule allosteric modulators that have shown activity against a broad range of disease models. Halia is led by an expert team of experienced and passionate scientists with decades of experience in drug discovery and development.

We have discovered a quickly growing pipeline of products, with each molecule offering differentiated benefits that potentially address a wide range of chronic inflammatory diseases. This portfolio of unique molecules offers advances in targeting, tissue distribution, and chemical structural diversity.

Chronic Inflammation Diagram

Inflammation is an essential biological response of our immune system that protects us against disease. However, when dysregulated inflammation can become a driver of disease by promoting a persistent, systemic immune response that fuels the development of many chronic diseases.

One of the primary mechanisms mediating the persistent, systemic inflammatory response is activating a large protein complex called the NLRP3 inflammasome. The inflammasome activation produces the maturation of pro-inflammatory signaling proteins called cytokines. The increase in the pro-inflammatory cytokines IL-1β and IL-18 resulting from NLRP3 inflammasome activation contributes considerably to disease-causing inflammation.

The NLRP3 inflammasome: an important and validated drug target

Over the past ten years, many scientific discoveries have revealed the NLRP3 inflammasome as a central upstream activator of the pro-inflammatory cytokines IL-1β and IL-18. NLRP3 has been validated as a viable therapeutic target that may overcome the limitations of many therapeutic strategies researched as treatments for chronic diseases.

Halia’s scientists have made important insights into NLRP3 biology, providing a new path for developing novel treatments for chronic inflammatory disease.

NLRP3 Inflammasome Process Chart

Halia’s Unique Chemical Approach

Halia’s pipeline of compounds was designed and discovered by our scientists by combining a novel protein binding mechanism with physiochemical properties needed for these compounds to be absorbed and distributed to target tissues in the body and even cross the blood-brain barrier. Halia is creating differentiated small molecules to treat chronic peripheral and CNS diseases with meaningful clinical opportunities and impact on patient lives.

Using this novel chemistry approach, we have translated the compounds to demonstrate their activity in assays and in vivo models readying them for clinical development.

Halia’s clinical team is led by leaders with deep expertise and experience in the design and execution of clinical trials to explore the activity of our pipeline of products.

Contact Us

Corporate Headquarters

3900 N. Traverse Mountain Blvd., Suite 100
Lehi, Utah 84043
United States |  +1 (385) 355-4315